Global Liver Cancer Drugs Market By Origin Type (Benign Liver Growths, Secondary, And Primary), By Type (Hepatoblastoma, Hepatocellular Carcinoma, Cholangio Carcinoma, And Other Types), By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, And Radiation Therapy), By End User (Adult, Pediatrics), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends And Forecast 2023-2032

Report Overview

Global Liver Cancer Drugs Market size is expected to be worth around USD 2,332 Million by 2032 from USD 980 Million in 2022, growing at a CAGR of 9.3% during the forecast period from 2023 to 2032.

The market was led by the United States among the top seven nations. Because, of significant trends such as fueling market expansion for the availability of innovative medications, the existence of a solid pipeline, and growing public cancer awareness. In addition, it is predicted that rising liver cancer rates brought on by a geriatric population and an unstructured lifestyle will boost the market.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• Liver cancer (hepatic cancer), also referred to as liver carcinoma, is one of the six most frequently occurring cancer types worldwide and treated using medications like Nexavar, Opdivo, Keytruda Stivarga Lenvima as therapeutic options.
• In 2022, the global liver cancer drugs market size was valued at USD 980 Million, and is projected to experience compound annual compounded annual growth at a compound annual compounded growth rate of 9.3 percent between 2023-2032.
• Key drivers include an increased global prevalence, rising diagnosis rates and new immunotherapy drugs; Hepatitis infections pose as one of the main risk factors.
• North America held the largest market share for 2021 due to high liver cancer diagnosis rates; however, Asia Pacific projected to experience the fastest compound annual compound annual compound annual growth due to rising liver cancer prevalence rates during forecast period.
• Nexavar by Bayer currently dominates with the highest market share. Immunotherapy drugs like Opdivo and Keytruda should see significant expansion.
• Drug development today emphasizes targeted therapies, combination therapies, immunotherapy treatments and vaccines as potential standards-of-care solutions. A diverse pipeline indicates potential innovation.

By Origin Analysis

The Secondary Segment Accounted for the Largest Market Share in Origin Type Owing to Secondary Cancers Cases being More Frequent

Based on Origin types, the Global Liver Cancer Drugs market is segmented into Benign Liver growth, Secondary, and Primary. Among these Origin Types, the largest market share was occupied by Secondary Segment in the forecast period. Because secondary cancers CASES are more frequent than primary liver cancer. Metastatic liver cancer is another name for secondary liver cancer.

By Type Analysis

The Hepatocellular Carcinoma Segment Accounted for the Largest Market Share By Type Owing to Its Most Therapeutic Effectiveness 

Based on types, the Global Liver Cancer Drugs market is segmented into Hepatocellular Carcinoma, Hepatoblastoma, Cholangio carcinoma, and Other Types. Among these types, the largest market share was occupied by the hepatocellular carcinoma Segment in the forecast period.

Because hepatocellular carcinoma patient has the most effective drug type for high Incidence of liver cancer. Nearly six additional occurrences of HCC are diagnosed in the general U.S. population per 100,000 people, according to the National Organization for Rare Diseases (NORD). Additionally, the market expansion during the analysis period is driven by the increased cancer cases and the increased unemployed medical demands.

By Therapy Analysis

The Targeted Therapy Segment Accounted for the Largest Market Share In Therapy Type Owing to Its Targeting Of Specific Molecular Alterations And Interferes With Particular Proteins Involved In Carcinogenesis

Based on Therapy, the Global Liver Cancer Drugs market is segmented into Targeted Therapy, Chemotherapy, Immunotherapy, and Radiation Therapy. Among these Therapy Types, the largest market share was occupied by the Targeted Therapy Segment in the forecast period.

Because of, the advantages that targeted therapy provides, such as how it targets specific molecular alterations that are specific to a given tumor and interferes with particular proteins involved in carcinogenesis. Also, Fewer side effects from treatment and the availability of numerous targeted treatments are two major factors that have influenced the expansion of the market for cancer medications.

By End User Analysis

The Targeted Therapy Segment Accounted for the Largest Market Share In End User Type Owing to Its Consumption Of Excessive Alcohol And Cigarette

Based on end users, the Global Liver Cancer Drugs market is segmented into adult and Pediatrics. Among these end-user Types, the largest market share was occupied by the adult Segment in the forecast period. Because adult individuals are consuming excessive alcohol consumption and cigarette.

Key Market Segments

By Origin Type

• Benign Liver Growths
• Secondary
• Primary

By Type

• Hepatocellular Carcinoma
• Hepatoblastoma
• Cholangio carcinoma
• Other Types

By Therapy

• Targeted Therapy
• Chemotherapy
• Immunotherapy
• Radiation Therapy

By End User

• Adult
• Pediatrics

Drivers

Mainly Caused by Smoking, Alcohol, And Increased Urbanisation

One million new cases of liver cancer are diagnosed worldwide each year. The debut of new drugs and rising FDA approvals for treating hepatocellular carcinoma, which accounts for nearly 90% of all liver cancer markets, are the results of the more aggressive R&D efforts against harmful diseases.

Liver cancer is mainly caused by smoking, alcohol, and increased urbanization. The global market for liver cancer drugs is being positively impacted by increased government help and investments from international healthcare institutions. The availability of many liver cancer drugs may soon increase demand.

Restraints

Growth Limiting Factor Like Strict Regulatory Procedures Restrains the Market

The main factors that will hinder market growth in the future are strict government regulations and a reduction in approvals for many small molecules and biologics within developed countries. Small-scale products without state-of-the-art equipment will likely face higher process errors, lack of quality, and increased pricing challenges which could hinder market growth.

Opportunity

Growing Investments Made by Different Pharmaceutical Companies In The Research And Development

Breast cancer, Lung cancer, colorectal cancer, and prostate cancer are the four most common forms of cancer. Additionally, the biopharmaceutical industry’s rapid progress has led to the creation of a variety of new medications that effectively target cancer cells while sparing healthy cells. The global market for cancer medications is expanding rapidly due to the growing public knowledge of the variety of cutting-edge treatments to fight cancer. Hence, it is anticipated that the growing investments made by different pharmaceutical companies in the research and development of various new cancer treatments would open up new growth opportunities.

Regional Analysis

North America Region Accounted Significant Share of The Global Liver Cancer Drugs Market

The biggest market for liver cancer drugs is in North America, preceded by markets in Europe, and Asia sequentially. The development of stronger healthcare infrastructure and a geriatric population are two factors that are primarily driving the market growth of the North American market. Because of the Y-O-Y rise in cases of liver cancer and the rising need for treatment, the United States currently dominates North America’s regional market.

Early adoption of cutting-edge diagnostic drugs and treatments for liver cancer helps the area become more strong. The Canadian market for medicines for liver cancer is second only to the American market in terms of size. The market participants put more emphasis on R&D activities to create innovative liver cancer drugs.

In 2022, the European region was the second-biggest regional market worldwide. The increase in funding for the creation of effective medicinal pharmaceuticals is responsible for the European market’s expansion. Furthermore, the market is being driven ahead by targeted drug therapy products.

The two leading economies in Europe are the United Kingdom and Germany. the U.K. is currently dominating the market and will continue to do so. The liver cancer drug market is anticipated to expand at the fastest CAGR in Germany and France.

Additionally, due to an increase in the number of geriatric people, Asia Pacific is the region with the greatest rate of increase in liver cancer drugs market growth. The market in the Asia Pacific region is also being fueled by an increase in liver cancer cases in Asian nations.

Other important reasons driving the growth of the APAC market are the increase in geriatric individuals and an increasing amount of clinical research on liver diseases, including cancer. For market participants in the business, China is an attractive location. the main thrust for market expansion is the broad base of the target audience and the crucial unsatisfied medical needs support.

the market for liver cancer drugs is anticipated to expand significantly in Latin America, the Middle East, and Africa. Because of Increasing financial support and investments in cancer research and development by both public and commercial organizations.

Key Regions

North America

• The US
• Canada
• Mexico

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Key Players Analysis

Till 2022, Bayer Will Continue to Hold The Top Spot In The Market

In this sector, some of the major firms include Bristol-Myers Squibb, Bayer, Exelixis, Eisai, and Merck. the companies are concentrating on product development Through clinical cooperation and expansion of business in emerging fields. Till 2022, Bayer AG will continue as a top prominent player in the market thanks to Stivarga’s approval as a second-line medication.

In 2020, Bayer’s Nexavar lost U.S. patent exclusivity, and as a result, sales will decline, resulting in a drop in Bayer’s market share by 2022. Tivarga is projected to become a second-line liver cancer treatment for Nexavar-tolerant patients who were still eligible for systemic therapy.

Market Key Players

With the presence of many local and regional players, the market for companion diagnostics is fragmented. Market players are subject to intense competition from top market players, particularly those with strong brand recognition and high distribution networks. To stay on top of the market, companies have gained various expansion strategies such as partnerships and product launches.

The following are some of the major players in the global liver cancer drug industry

• Eli Lilly and Company
• Exelixis Inc.
• Merck & Co. Inc.
• Pfizer Inc.
• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Johnson & Johnson
• Sanofi SA
• Novartis AG
• SillaJenF
• Hoffmann-La Roche Ltd
• Bayer AG
• Celsion Corporation
• Eisai Co. Ltd,
• Other Key Players

Recent Development

• Jan 2023, SURVCAN-3 a population based study in32 countries for survival of cancer in Central & South America, Africa and Asia by Global Cancer Observatory
• Jan 2022, On the basis of its second confirmatory research, Merck gained conditional clearance for the liver cancer therapy medicine Keytruda. In Asia region, hepatocellular carcinoma’s patients, reduced the risk of death by 21% by Keytruda.
• Mar 2021, Glass Microspheres TheraSphere Y-90 , manufactured by Boston Scientific Corporation for the care of patients with hepatocellular cancer (HCC), have been given FDA approval.

Report Scope